These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17982198)

  • 21. [Recent progress in the treatment of rheumatoid arthritis].
    Tanaka Y
    Clin Calcium; 2012 Feb; 22(2):169-78. PubMed ID: 22298069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical development and future perspective of biological agents].
    Takeuchi T
    Nihon Rinsho; 2007 Jul; 65(7):1185-8. PubMed ID: 17642230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Serum markers of synovitis and bone metabolism in rheumatoid arthritis].
    Kotake S; Nanke Y; Yago T; Yamanaka H
    Clin Calcium; 2009 Mar; 19(3):362-71. PubMed ID: 19252246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [RANKL inhibition as therapy for joint damage].
    Akama H
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Oct; 30(5):404-7. PubMed ID: 17984581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Daily practice using the guidelines for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis].
    Soen S
    Clin Calcium; 2008 Aug; 18(8):1169-75. PubMed ID: 18677056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-interleukin-6 therapy in rheumatoid arthritis.
    Woodrick R; Ruderman EM
    Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy.
    Popa C; Netea MG; Barrera P; Radstake TR; van Riel PL; Kullberg BJ; Van der Meer JW
    Cytokine; 2005 Apr; 30(2):72-7. PubMed ID: 15804598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-6 in rheumatoid arthritis.
    Nishimoto N
    Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-cytokine therapy for rheumatoid arthritis.
    Maini RN; Taylor PC
    Annu Rev Med; 2000; 51():207-29. PubMed ID: 10774461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
    Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
    Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
    Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
    Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biological agents targeting on pro-inflammatory cytokines].
    Takeuchi T
    Nihon Rinsho; 2005 Sep; 63(9):1601-6. PubMed ID: 16164218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
    Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-TNF scintigraphy to assess TNF-α-associated joint inflammation in rheumatoid arthritis and osteoarthritis.
    Hermann J; Lipp RW; Dunzinger A; Spreizer C; Schaffler G; Kvaternik H; Ofner P; Graninger W
    Clin Exp Rheumatol; 2014; 32(4):614. PubMed ID: 24959905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.